Compare Nuscale Power Corporation (SMR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs TransMedics Group Inc — how do they compare? Nuscale Power Corporation trades at $8.8 (market cap $2.76B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Nuscale Power Corporation and TransMedics Group Inc are close in size by market cap, and TransMedics Group Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| SMR | TMDX | |
|---|---|---|
Market Cap | $2.76B | $2.54B |
Sector | Utilities | Technology |
52-Week High | $53.43 | $150.42 |
52-Week Low | $7.64 | $61.99 |
Enterprise Value | $1.87B | $2.94B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
